SHPG - Shire plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
166.22
-3.86 (-2.27%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close170.08
Open166.92
Bid0.00 x 800
Ask0.00 x 1000
Day's Range165.29 - 167.21
52 Week Range123.73 - 182.47
Volume4,112,660
Avg. Volume1,386,874
Market Cap51.506B
Beta (3Y Monthly)0.79
PE Ratio (TTM)10.56
EPS (TTM)15.74
Earnings DateN/A
Forward Dividend & Yield1.06 (0.61%)
Ex-Dividend Date2018-09-06
1y Target Est200.27
Trade prices are not sourced from all markets
  • Benzinga16 hours ago

    Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

    Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...

  • GlobeNewswire23 hours ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire2 days ago

    FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)

    Motegrity, a selective serotonin-4 (5-HT4) receptor agonist, provides a different class of treatment for CIC that works by enhancing colonic peristalsis to increase bowel motility.1-3 Motegrity is expected to launch in 2019 in the United States, where an estimated 35 million adults are living with CIC.4,5* While not all patients may be right for treatment, Motegrity represents an important new option. “The approval of Motegrity marks a new day in the treatment of CIC,” said Howard Mayer, M.D., Senior Vice President and Chief Medical Officer, Shire.

  • Moody's2 days ago

    Takeda Pharmaceutical Company Limited -- Moody's downgrades Takeda to Baa2; outlook stable

    Moody's Japan K.K. has downgraded to Baa2 from A2 the issuer and senior unsecured ratings of Takeda Pharmaceutical Company Limited. At the same time, Moody's has changed the ratings outlook to stable. "This transformative acquisition will cause Takeda's debt to increase almost six-fold, making the company one of the most leveraged pharmaceutical companies rated investment grade," says Moody's analyst Yukiko Asanuma.

  • GlobeNewswire5 days ago

    Director/PDMR Shareholding

    Director/PDMR Shareholding December 14, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) Notification of transactions by person discharging managerial.

  • GlobeNewswire5 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of SHP.L earnings conference call or presentation 31-Jul-18 1:00pm GMT

    Q2 2018 Shire PLC Earnings Call

  • GlobeNewswire6 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire7 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • TheStreet.com8 days ago

    Shire, Abbott Labs May Pace Healthcare Stocks in 2019

    Shire is a pharmaceutical company, with a wide range of products approved for use around the world. Some of the more familiar drugs the company produces include Adderall, prescribed for adult ADD, and Pentasa, used to treat Crohn's and other inflammatory bowel diseases. The company possesses both strength and weakness, and both are evident in the most recent quarterly report.

  • GlobeNewswire8 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire12 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
    Zacks13 days ago

    Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger

    Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.

  • GlobeNewswire13 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Takeda Downgrade Looms After Shareholders Approve Shire Deal
    Bloomberg13 days ago

    Takeda Downgrade Looms After Shareholders Approve Shire Deal

    The backing of what will be the largest-ever overseas purchase by a Japanese company paves the way for possible downgrades to the lowest tiers before junk ratings at both S&P Global Ratings and Moody’s Investors Service. What happens after that depends on how quickly Takeda can reduce its debt burden, including progress in potential non-core asset sales worth up to $10 billion, analysts at the ratings companies say. Takeda pulled off a mammoth dollar- and euro-note bond sale last month, and NLI Research Institute said investors are interested in how much the acquisition ultimately benefits the Japanese drug maker.

  • Is the Options Market Predicting a Spike in Shire (SHPG) Stock?
    Zacks14 days ago

    Is the Options Market Predicting a Spike in Shire (SHPG) Stock?

    Investors need to pay close attention to Shire (SHPG) stock based on the movements in the options market lately.

  • Takeda's Long Battle for $62 Billion Shire Deal Gets Victory
    Bloomberg14 days ago

    Takeda's Long Battle for $62 Billion Shire Deal Gets Victory

    Now the Frenchman has emerged victorious as 88 percent of Takeda shareholders voted in support of the acquisition, virtually ending Weber’s nine-month campaign to secure Shire, whose investors overwhelmingly backed the deal. The Takeda vote represents a clear endorsement of Weber’s vision to transform the 237-year-old company into a top 10 drugmaker with lucrative therapies for rare diseases and a sizable footprint in the U.S. The scope of the combination underscores Weber’s ambitions: it’s the biggest acquisition announced globally this year and the largest overseas takeover ever by a Japanese company.

  • Takeda, Shire shareholders approve $62B tie-up
    American City Business Journals14 days ago

    Takeda, Shire shareholders approve $62B tie-up

    Barring significant layoffs, the combined company will likely surpass Sanofi as the largest life sciences employer in Massachusetts.

  • Financial Times14 days ago

    [$$] Takeda wins shareholder approval for £46bn Shire acquisition

    by founding family members to derail a deal that the 237-year-old group sees as pivotal to securing its place among the world’s top 10 pharmaceutical companies. Following an extraordinary meeting in Osaka, Takeda said it had won approval from nearly 90 per cent of its shareholders to issue new shares to acquire the Irish drugmaker. “The Japanese market represents 7 per cent of the global market.

  • Investing.com14 days ago

    Asian Stocks Decline Even After China Expresses Confidence to Reach Trade Deal

    Investing.com - Asian stocks declined in afternoon trade on Wednesday even after China expressed confidence that it could reach a trade deal with the U.S.

  • GlobeNewswire14 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire15 days ago

    Holding(s) in Company

    Holding(s) in Company December 4, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are.

  • GlobeNewswire15 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Shire's Takhzyro Gets European Nod for Hereditary Angioedema
    Zacks16 days ago

    Shire's Takhzyro Gets European Nod for Hereditary Angioedema

    Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.